NICE continues to muddy the waters of osteoporosis

Osteoporosis International

Volumn 19, Issue 8, 2008, Pages 1105-1107

  Kanis, J A ^a   Compston, J E ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; EDITORIAL; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION;

BONE DENSITY CONSERVATION AGENTS; EVIDENCE-BASED MEDICINE; FRACTURES, BONE; GOVERNMENT AGENCIES; GREAT BRITAIN; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 46649094559     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0649-4     Document Type: Editorial

References (26)

1. Delmas PD, Siris ES (2008) NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone 42:16-18
2. National Institute for Health and Clinical Excellence (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (June)
3. National Institute for Health and Clinical Excellence (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (June)
4. National Institute for Health and Clinical Excellence (2008) Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (March)
5. National Institute for Health and Clinical Excellence (2008) Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London (March)
6. House of Commons Health Committee, National Institute for Health and Clinical Excellence (2008) First Report of Session 2007-08, vol. 1. HC 27-I. The Stationery Office Limited, London. Available from http://www.publications. parliament.uk/pa/cm200708/cmselect/cmhealth/27/27.pdf. Accessed 20 April
7. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) Cost-effectiveness of alendronate. Bone 42:4-15
8. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Corticosteroid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11(7):1-256
9. Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK
10. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
11. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) Modelling cost-effectiveness for osteoporosis. Bone (in press)
12. Stevenson M (2008) The population of health economic models is critical. Bone (in press)
13. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 18:9-23
14. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733
15. Zethraeus N, Ström O, Borgström F, Kanis JA, Jönsson B (2008) The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. Osteoporos Int (in press)
16. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429-448
17. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447
18. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449-458
19. Leslie WD (2008) Manitoba Bone Density Program Committee. Absolute fracture risk reporting in clinical practice: a physician-centered survey. Osteoporos Int 19:459-463
20. Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G, Brown JP (2007) Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10:120-123
21. Nakamura T, World Health Organization (2007) Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006. Clin Calcium 17:1022-1028
22. Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36:683-690
23. Czerwiński E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J (2007) Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9:337-356
24. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
25. National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset (2008) Osteoporosis: clinical guideline for prevention and treatment. Circulated for consultation
26. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A and the National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX™-assessment and intervention thresholds for the UK. Osteoporos Int (in press)